Glenmark Pharmaceuticals Ltd. (Glenmark), an innovation-driven, global pharmaceuticals company, has further strengthened its position in the respiratory segment and is ranked #2 in the Indian pharma market*. Glenmark is a trusted brand for its respiratory medicines with brands like Ascoril, Ascoril LS, Ascoril D and Alex. The company’s modern and innovative solutions, Bilazap M and Ryaltris AZ/Mono are also popular among patients and healthcare professionals. Over the past one year, its respiratory medicines have been prescribed by more than 1 lakh medical professionals and have helped over4crore patients from all age groups across the country.
Glenmark is a pioneer in modern OAD management in India, and is one of the first companies to address unmet patient needs in asthma and COPD. They have introduced innovative products in the chronic respiratory space, such as Digital Dose Inhalers, Ultra LABA + ICS, Single Inhaler Triple Therapy, and Nebulised LAMA, which have helped patients with chronic respiratory conditions breathe better and manage their symptoms more effectively.
India has the highest global burden of respiratory diseases, largely due to pollution. Mr. Alok Malik, Executive Vice President and India Business Head at Glenmark Pharmaceuticals Ltd, said, “We are driven by our goal of providing first-in-market medicines for our patients and will continue to bring new medicines that are safe and effective.”